Laurus Labs Ltd (BOM:540222) reports robust financial results with significant growth in its generic division and strategic investments in advanced therapies.

Revenues for the quarter rose 26 percent to Rs.1,778 crore, supported by broad‑based strength across the generics and CDMO businesses.

In its investor presentation, Laurus Labs said that they are well on track to deliver healthy operational growth for financial year 2026.

The final trading day of the week promises to be full of action with regards to quarterly results, with over 50 companies ...

Laurus Labs Ltd. on Friday posted a remarkable surge in net profit for the first nine months of FY26, driven by strong momentum in its Generics and CDMO businesses.

Laurus Labs Q3 FY26: Revenue Up 30% YoY, Margins Expand to 26.1% 📈 | MCap 54,914.21 Cr - 9M FY26 revenue: ₹5,001 Cr, up 30% ...

LAURUS LABS LTD - Board Meeting Intimation for Inter-Alia To Consider The Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2025 - Rediff MoneyWiz, the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Revenue: INR 1,653 crore for Q2 FY26, reflecting robust demand. Gross Margin: Expanded further, maintained well above 59% range. Operating Margin: Expanded by 11 percentage points to 26%. CDMO Revenue ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...